All elements of the P01 are coordinated through the Administrative Core. Its purpose is to ensure the efficient execution of the P01 and to manage the overall budget. The Administrative Core is designed to be and serves as the central site for the planning, direction, communication, and general review of the P01. This role includes the organization of meetings for scientific review (both internal and external), overseeing the budget of all associated components, adhering to established timelines and regulatory requirements, and facilitating communication amongst the Principal Investigators and Core Directors. The Administrative Core will perform three main functions 1) Scientific leadership, 2) Administrative leadership, and 3) Clinical coordination. These functions will be accomplished through the following Specific Aims: 1. Provide scientific leadership to and oversight of the research projects and cores of the program. 2. Convene all meetings for the Executive Committee, the Internal Advisory Board, the External Advisory Board, regular meetings with the investigators, selected consultants, and key personnel, and various other meetings to promote scientific exchange and implement committee recommendations, as appropriate. 3. Maintain fiscal and budgetary management in coordination with the Office Research Administration and Grants &Contracts Accounting at M. D. Anderson Cancer Center. 4. Ensure compliance with all general, institutional, governmental, and specific NIH regulations and requirements. 5. Provide oversight and coordination for all clinical research efforts. Dr. Patrick Hwu will lead the Administrative Core providing leadership and general administration of all activities relating to the P01.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA128913-04
Application #
8332333
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$142,254
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Huang, L; Wang, Z; Liu, C et al. (2017) CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene 36:4081-4086
Peng, Weiyi; Chen, Jie Qing; Liu, Chengwen et al. (2016) Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6:202-16
Meller, Stephan; Di Domizio, Jeremy; Voo, Kui S et al. (2015) T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol 16:970-9
Singh, Manisha; Overwijk, Willem W (2015) Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother 64:911-21
Lande, Roberto; Chamilos, Georgios; Ganguly, Dipyaman et al. (2015) Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol 45:203-13
Singh, Manisha; Khong, Hiep; Dai, Zhimin et al. (2014) Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J Immunol 193:4722-31
Hailemichael, Yared; Overwijk, Willem W (2013) Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology 2:e24743
Radvanyi, Laszlo; Pilon-Thomas, Shari; Peng, Weiyi et al. (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter. Clin Cancer Res 19:5541
Hailemichael, Yared; Dai, Zhimin; Jaffarzad, Nina et al. (2013) Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med 19:465-72
Yang, Yan; Liu, Chengwen; Peng, Weiyi et al. (2012) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120:4533-43

Showing the most recent 10 out of 23 publications